HIMS CEO Form 4: 108,334 and 17,001 options exercised; sales filed

Rhea-AI Filing Summary

Hims & Hers Health (HIMS) CEO and 10% owner Andrew Dudum reported multiple insider transactions on 10/16/2025 under a Rule 10b5-1 plan adopted on August 28, 2024. He exercised stock options at an exercise price of $2.43 and sold shares in several tranches at weighted average prices disclosed within ranges, including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.

Reported option exercises included 108,334 and 17,001 shares, followed by sales such as 39,531, 39,332, 39,111, 17,001, and smaller lots. After the transactions, reported direct holdings included 109,190 shares, with additional indirect holdings across multiple family trusts, each listed with its own balance.

Insights

Insider trading compliance analyst

Routine Form 4 under a pre-set 10b5-1 plan.

The CEO executed option exercises at an exercise price of $2.43 and sold shares in multiple trades on 10/16/2025. The filing states the activity was effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024, indicating pre-arranged instructions.

Weighted-average sale prices are provided in ranges (e.g., $62.50–$62.87 and $63.31–$63.59) with an undertaking to furnish full breakdowns upon request. This is standard disclosure and does not indicate issuer cash inflow.

Post-transaction, direct holdings are reported alongside multiple indirect trust holdings. Market impact depends on trade size relative to daily volume; actual effects will be determined by market conditions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dudum Andrew

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	10/16/2025		S(1)		2,792	D	$62.6518(2)	92,523	D
Class A Common Stock	10/16/2025		S(1)		39,111	D	$62.6997(3)	55,947	I	Held by Trustee of Dudum Family Community Property Trust
Class A Common Stock	10/16/2025		S(1)		8,423	D	$63.4588(4)	47,524	I	Held by Trustee of Dudum Family Community Property Trust
Class A Common Stock	10/16/2025		M(1)		17,001	A	$2.43	109,524	D
Class A Common Stock	10/16/2025		S(1)		17,001	D	$62.69(5)	92,523	D
Class A Common Stock	10/16/2025		M(1)		108,334	A	$2.43	200,857	D
Class A Common Stock	10/16/2025		S(1)		39,531	D	$62.7053(6)	161,326	D
Class A Common Stock	10/16/2025		S(1)		10,469	D	$63.4852(7)	150,857	D
Class A Common Stock	10/16/2025		S(1)		39,332	D	$62.6999(8)	111,525	D
Class A Common Stock	10/16/2025		S(1)		2,335	D	$63.3873(9)	109,190	D
Class A Common Stock	10/16/2025		S(1)		16,667	D	$62.6969(5)	92,523	D
Class A Common Stock								1,194,545	I	Held by Trustee of AD 2022 GRAT 3 dated 11-28-2022
Class A Common Stock								1,016,871	I	Held by Trustee of Andrew Dudum 2015 Trust Dated July 2, 2015
Class A Common Stock								1,286,627	I	Held by Trustee of AD 2021 GRAT dated 11-1-2021
Class A Common Stock								186,723	I	Held by Trustee of AD 2025 GRAT dated 5-27-2025
Class A Common Stock								508,030	I	Held by Trustee of AD 2022 GRAT
Class A Common Stock								321,657	I	Held by Trustee of AD 2021 GRAT 2 dated 11-1-2021
Class A Common Stock								1,584,506	I	Held by Trustee of AD 2023 GRAT dated 9-5-2023

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.43	10/16/2025		M(1)			17,001	(10)	06/16/2030	Class A Common Stock	17,001	$0	17,005	D
Stock Option (right to buy)	$2.43	10/16/2025		M(1)			108,334	(11)	06/16/2030	Class A Common Stock	108,334	$0	431,395	D

Explanation of Responses:

1. The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.

2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.50 - $62.87. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.215 - $63.13. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.31 - $63.59. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.25 - $62.94. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.18. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.25 - $63.63. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $62.22 - $63.20. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

9. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $63.26 - $63.47. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

10. Prior to the Company's business combination transaction in 2021, the option represented the right to purchase 7,166,182 shares of Hims, Inc. with an exercise price of $1.10. Following the Company's business combination transaction in 2021, the option converted into the right to purchase 3,246,139 shares of the Company with an exercise price of $2.43. 100% of the shares subject to the option vested upon certain specified thresholds met in 2021.

11. The Stock Option was received in exchange for an option to purchase 3,583,091 shares of Class A Common Stock of Hims, Inc., with an exercise price of $1.10, in connection with the Merger. 1/48 of the shares subject to the Stock Option vest when the Reporting Person completes each month of continuous Service beginning March 13, 2020.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Andrew Dudum	10/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HIMS CEO Andrew Dudum report on Form 4?

He exercised stock options at an exercise price of $2.43 and sold shares in multiple tranches on 10/16/2025 under a Rule 10b5-1 plan.

Were the HIMS insider sales under a 10b5-1 plan?

Yes. The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.

What price ranges did the HIMS insider sales occur at?

Weighted-average sale prices were disclosed in ranges including $62.50–$62.87, $62.215–$63.13, and $63.31–$63.59.

How many HIMS options were exercised by the CEO?

Reported exercises included 108,334 and 17,001 shares at an exercise price of $2.43.

What are the CEO’s reported direct HIMS holdings after the transactions?

The filing shows 109,190 shares held directly after the reported transactions.

Did the CEO have indirect HIMS holdings?

Yes. The filing lists multiple indirect holdings across family trusts, each reported with its own share balance.